MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes

Journal of Magnetic Resonance Imaging

Volumn 43, Issue 5, 2016, Pages 1090-1099

  Vu, Kim Nhien ^a   Gilbert, Guillaume ^a,b   Chalut, Marianne ^a   Chagnon, Miguel ^c   Chartrand, Gabriel ^a   Tang, An ^a,d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b PHILIPS HEALTHCARE   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

fat quantification; heterogeneity; MRI; MRS; nonalcoholic fatty liver disease; proton density fat fraction

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER LOBE; LIVER MEAN PROTON DENSITY FAT FRACTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROCEDURES, PARAMETERS AND DEVICES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGION OF INTEREST; RETROSPECTIVE STUDY; SAMPLING; WHOLE LIVER SEGMENTATION; ADIPOSE TISSUE; ANALYSIS OF VARIANCE; ANIMAL; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; LIVER; METABOLISM; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBSERVER VARIATION; PATHOLOGY; RAT; STANDARD; YOUNG ADULT;

BIOLOGICAL MARKER; PROTON;

ADIPOSE TISSUE; ADULT; AGED; ANALYSIS OF VARIANCE; ANIMALS; BIOMARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBSERVER VARIATION; PROTONS; RATS; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84963828939     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.25083     Document Type: Article

References (57)

1. Preiss D, Sattar N,. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008; 115: 141-150.
2. Marchesini G, Brizi M, Bianchi G, et al., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
3. Targher G, Bertolini L, Padovani R, et al., Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.
4. Farrell GC, Larter CZ,. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
5. Bravo AA, Sheth SG, Chopra S,. Liver biopsy. N Engl J Med 2001; 344: 495-500.
6. Mato JM, Lu SC,. Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers? Hepatology 2011; 54: 1115-1117.
7. Ratziu V, Cadranel JF, Serfaty L, et al., A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol 2012; 57: 376-383.
8. Noureddin M, Lam J, Peterson MR, et al., Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58: 1930-1940.
9. Reeder SB, Cruite I, Hamilton G, Sirlin CB,. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011; 34: 729-749.
10. Longo R, Pollesello P, Ricci C, et al., Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281-285.
11. d'Assignies G, Kauffmann C, Boulanger Y, et al., Simultaneous assessment of liver volume and whole liver fat content: a step towards one-stop shop preoperative MRI protocol. Eur Radiol 2011; 21: 301-309.
12. Tang A, Tan J, Sun M, et al., Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013; 267: 422-431.
13. Tang A, Chen J, Le TA, et al., Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. Abdom Imaging 2015; 40: 26-37.
14. Belfort R, Harrison SA, Brown K, et al., A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 30: 2297-2307.
15. Ryan MC, Itsiopoulos C, Thodis T, et al., The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59: 138-143.
16. Bacchi E, Negri C, Targher G, et al., Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013; 58: 1287-1295.
17. Loomba R, Sirlin CB, Ang B, et al., Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015; 61: 1239-1250.
18. Le TA, Chen J, Changchien C, et al., Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012; 56: 922-932.
19. Tang A, Rabasa-Lhoret R, Castel H, et al., Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial. Diabetes Care 2015; 38: 1339-1346.
20. Yokoo T, Shiehmorteza M, Hamilton G, et al., Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 2011; 258: 749-759.
21. van Werven JR, Marsman HA, Nederveen AJ, et al., Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 2010; 256: 159-168.
22. Yoshimitsu K, Kuroda Y, Nakamuta M, et al., Noninvasive estimation of hepatic steatosis using plain CT vs. chemical-shift MR imaging: significance for living donors. J Magn Reson Imaging 2008; 28: 678-684.
23. McPherson S, Jonsson JR, Cowin GJ, et al., Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J Hepatol 2009; 51: 389-397.
24. O'Regan DP, Callaghan MF, Wylezinska-Arridge M, et al., Liver fat content and T2: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T-feasibility. Radiology 2008; 247: 550-557.
25. Meisamy S, Hines CD, Hamilton G, et al., Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011; 258: 767-775.
26. Lee SS, Park SH, Kim HJ, et al., Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010; 52: 579-585.
27. Hwang I, Lee JM, Lee KB, et al., Hepatic steatosis in living liver donor candidates: preoperative assessment by using breath-hold triple-echo MR imaging and 1H MR spectroscopy. Radiology 2014; 271: 730-738.
28. Hines CD, Frydrychowicz A, Hamilton G, et al., T(1) independent, T(2) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging 2011; 33: 873-881.
29. Qayyum A, Goh JS, Kakar S, Yeh BM, Merriman RB, Coakley FV,. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques-initial experience. Radiology 2005; 237: 507-511.
30. Kang GH, Cruite I, Shiehmorteza M, et al., Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J Magn Reson Imaging 2011; 34: 928-934.
31. Bonekamp S, Tang A, Mashhood A, et al., Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging 2014; 39: 1525-1532.
32. Permutt Z, Le TA, Peterson MR, et al., Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36: 22-29.
33. Idilman IS, Aniktar H, Idilman R, et al., Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013; 267: 767-775.
34. Merriman RB, Ferrell LD, Patti MG, et al., Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-880.
35. Ratziu V, Charlotte F, Heurtier A, et al., Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
36. Szczepaniak LS, Nurenberg P, Leonard D, et al., Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-468.
37. van Werven JR, Hoogduin JM, Nederveen AJ, et al., Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content. J Magn Reson Imaging 2009; 30: 444-448.
38. Johnson BL, Schroeder ME, Wolfson T, et al., Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2-corrected, spectrum-modeled MRI. J Magn Reson Imaging 2014; 39: 440-447.
39. Vanhamme L, van den Boogaart A, Van Huffel S,. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997; 129: 35-43.
40. Naressi A, Couturier C, Devos JM, et al., Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 12: 141-152.
41. 1H MR spectrum. NMR Biomed 2011; 24: 784-790.
42. Yokoo T, Bydder M, Hamilton G, et al., Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009; 251: 67-76.
43. Bydder M, Yokoo T, Yu H, Carl M, Reeder SB, Sirlin CB,. Constraining the initial phase in water-fat separation. Magn Reson Imaging 2010; 29: 216-221.
44. Reeder SB, Hu HH, Sirlin CB,. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging 2012; 36: 1011-1014.
45. Reeder SB, Robson PM, Yu H, et al., Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 2009; 29: 1332-1339.
46. Artz NS, Haufe WM, Hooker CA, et al., Reproducibility of MR-based liver fat quantification across field strength: same-day comparison between 1.5T and 3T in obese subjects. J Magn Reson Imaging 2015; 42: 811-817.
47. Kühn JP, Hernando D, Mensel B, et al., Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis. J Magn Reson Imaging 2014; 39: 1494-1501.
48. Guiu B, Petit JM, Loffroy R, et al., Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 2009; 250: 95-102.
49. Bastati N, Feier D, Wibmer A, et al., Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 2014; 271: 739-747.
50. Nomura F, Ohnishi K, Ochiai T, Okuda K,. Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet. Radiology 1987; 162: 845-847.
51. Hermoye L, Laamari-Azjal I, Cao Z, et al., Liver segmentation in living liver transplant donors: comparison of semiautomatic and manual methods. Radiology 2005; 234: 171-178.
52. Heimann T, van Ginneken B, Styner MA, et al., Comparison and evaluation of methods for liver segmentation from CT datasets. IEEE Trans Med Imaging 2009; 28: 1251-1265.
53. Gotra A, Chartrand G, Massicotte-Tisluck K, et al., Validation of a semiautomated liver segmentation method using CT for accurate volumetry. Acad Radiol 2015; 22: 1088-1098.
54. Fananapazir G, Bashir MR, Marin D, Boll DT,. Computer-aided liver volumetry: performance of a fully-automated, prototype post-processing solution for whole-organ and lobar segmentation based on MDCT imaging. Abdom Imaging 2015; 40: 1203-1212.
55. El-Badry AM, Breitenstein S, Jochum W, et al., Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009; 250: 691-697.
56. Lee SS, Lee Y, Kim N, et al., Hepatic fat quantification using chemical shift MR imaging and MR spectroscopy in the presence of hepatic iron deposition: validation in phantoms and in patients with chronic liver disease. J Magn Reson Imaging 2011; 33: 1390-1398.
57. Kang BK, Yu ES, Lee SS, et al., Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. Invest Radiol 2012; 47: 368-375.